SE447256B - 2-fenoxialkyl-1,2,4-triazol-3-oner, deras framstellning och farmaceutisk komposition derav - Google Patents

2-fenoxialkyl-1,2,4-triazol-3-oner, deras framstellning och farmaceutisk komposition derav

Info

Publication number
SE447256B
SE447256B SE8201631A SE8201631A SE447256B SE 447256 B SE447256 B SE 447256B SE 8201631 A SE8201631 A SE 8201631A SE 8201631 A SE8201631 A SE 8201631A SE 447256 B SE447256 B SE 447256B
Authority
SE
Sweden
Prior art keywords
formula
chlorophenyl
triazol
ethyl
propyl
Prior art date
Application number
SE8201631A
Other languages
English (en)
Swedish (sv)
Other versions
SE8201631L (sv
Inventor
Jr D L Temple
Jr W G Lobeck
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22922879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE447256(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of SE8201631L publication Critical patent/SE8201631L/xx
Publication of SE447256B publication Critical patent/SE447256B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/067—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8201631A 1981-03-16 1982-03-15 2-fenoxialkyl-1,2,4-triazol-3-oner, deras framstellning och farmaceutisk komposition derav SE447256B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/244,464 US4338317A (en) 1981-03-16 1981-03-16 Phenoxyethyl-1,2,4,-triazol-3-one antidepressants

Publications (2)

Publication Number Publication Date
SE8201631L SE8201631L (sv) 1982-09-17
SE447256B true SE447256B (sv) 1986-11-03

Family

ID=22922879

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8201631A SE447256B (sv) 1981-03-16 1982-03-15 2-fenoxialkyl-1,2,4-triazol-3-oner, deras framstellning och farmaceutisk komposition derav

Country Status (26)

Country Link
US (1) US4338317A (fr)
JP (1) JPS57159774A (fr)
KR (1) KR880001374B1 (fr)
AT (1) AT384022B (fr)
BE (1) BE892503A (fr)
CA (1) CA1198436A (fr)
CH (1) CH649539A5 (fr)
CY (1) CY1373A (fr)
DE (1) DE3209557A1 (fr)
DK (1) DK158728C (fr)
ES (1) ES8305756A1 (fr)
FI (1) FI73670C (fr)
FR (1) FR2501690B1 (fr)
GB (1) GB2096137B (fr)
GR (1) GR76076B (fr)
HK (1) HK4788A (fr)
IE (1) IE52788B1 (fr)
IT (1) IT1148137B (fr)
KE (1) KE3711A (fr)
LU (1) LU84011A1 (fr)
MX (1) MX9203176A (fr)
NL (2) NL190757C (fr)
SE (1) SE447256B (fr)
SG (1) SG30287G (fr)
YU (1) YU43256B (fr)
ZA (1) ZA821359B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399693A (en) * 1984-04-17 1995-03-21 British Technology Group Limited Substituted piperazine-2-carboxylic acids and derivatives thereof

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4487773A (en) * 1981-03-16 1984-12-11 Mead Johnson & Company 1,2,4-Triazol-3-one antidepressants
US4386091A (en) * 1982-02-24 1983-05-31 Mead Johnson & Company 2-Phenoxyalkyl-1,2,4-triazol-3-one antidepressants
US4575555A (en) * 1983-06-29 1986-03-11 Mead Johnson & Company 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
AT388555B (de) * 1983-06-29 1989-07-25 Bristol Myers Co Verfahren zur herstellung von neuen 1,2,4-triazol-3-on-derivaten
US4613600A (en) * 1983-09-30 1986-09-23 Mead Johnson & Company Antidepressant 1,2,4-triazolone compounds
YU44721B (en) * 1983-11-30 1990-12-31 Bristol Myers Co Process for obtaining 4-(2-phenoxyethyl)-1,2,4-triazolone
US4784998A (en) * 1987-04-06 1988-11-15 Bristol-Myers Company 1,3,4-oxadiazole pyschotropic compounds
US5116852A (en) * 1990-12-03 1992-05-26 Bristol-Myers Squibb Co. Treatment of sleep disorders
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
US5256664A (en) * 1992-04-28 1993-10-26 Bristol-Myers Squibb Company Antidepressant 3-halophenylpiperazinylpropyl derivatives of substituted triazolones and triazoldiones
IT1256387B (it) * 1992-11-13 1995-12-04 Acraf Procedimento per preparare triazoloni
CA2160423A1 (fr) * 1994-11-02 1996-05-03 Hemant N. Joshi Sels de nefazodone a taux de dissolution ameliores
AU7025396A (en) 1995-10-17 1997-05-01 Bristol-Myers Squibb Company Nefazodone: treatment of panic attack
CA2182241C (fr) * 1996-07-29 2002-09-17 Bo Lei Methodes pour la preparation de nefazodone
WO1998004261A1 (fr) * 1996-07-31 1998-02-05 Bristol-Myers Squibb Company Utilisation de la nefazodone dans la prophylaxie de la migraine
US5852020A (en) * 1996-11-22 1998-12-22 Bristol-Myers Squibb Company Nefazodone: use in treating post traumatic stress disorder
US5735873A (en) * 1996-12-19 1998-04-07 Maclean; David S. Surgical tool handle
US5917050A (en) * 1998-02-11 1999-06-29 Bayer Corporation Process for preparing alkoxytriazolinones
ES2152860B1 (es) * 1998-10-23 2001-08-16 Finaf 92 Sa Forma cristalina de la nefazodona y procedimiento para su preparacion.
US6706282B1 (en) 1998-11-02 2004-03-16 Evangeline Cruz Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones
US6469008B2 (en) 1999-04-09 2002-10-22 Sepracor Inc. (R)-hydroxynefazodone antipsychotic therapy
DE60028955T2 (de) * 1999-04-09 2007-07-05 Sepracor Inc., Marlborough R-hydroxynefazodon
US6586437B2 (en) 1999-04-09 2003-07-01 Sepracor Inc. (S)-hydroxynefazodone antipsychotic therapy
US6465469B1 (en) 1999-04-09 2002-10-15 Sepracor Inc. S-hydroxynefazodone
CA2356450C (fr) 2001-09-10 2003-11-25 Brantford Chemicals Inc. Synthese amelioree de chlorhydrate de nefazodone
WO2003099265A2 (fr) * 2002-05-24 2003-12-04 Coester Carl-Fr Combinaison d'agents actifs pharmaceutiques et utilisation
GB0306604D0 (en) * 2003-03-21 2003-04-30 Curidium Ltd Second medical use
CN1780818A (zh) * 2003-04-30 2006-05-31 Fmc有限公司 苯基取代的环状衍生物
US7671072B2 (en) * 2003-11-26 2010-03-02 Pfizer Inc. Aminopyrazole derivatives as GSK-3 inhibitors
CA2567249A1 (fr) * 2004-04-19 2006-10-05 Jds Pharmaceuticals, Llc Combinaisons de lithium et utilisations associees
AR049382A1 (es) * 2004-05-18 2006-07-26 Fmc Corp Derivados de la urea ciclica substituida
EP2317316A3 (fr) 2005-07-08 2011-06-15 Braincells, Inc. Procédés permettant d'identifier l'agent et les conditions qui modulent la neurogénèse
EP1940389A2 (fr) 2005-10-21 2008-07-09 Braincells, Inc. Modulation de la neurogenese par inhibition de la pde
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
MX2009002496A (es) 2006-09-08 2009-07-10 Braincells Inc Combinaciones que contienen un derivado de 4-acilaminopiridina.
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (fr) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation de la neurogenèse par des ligands mélatoninergiques
EP2125017A2 (fr) * 2007-01-11 2009-12-02 Braincells, Inc. Modulation de la neurogenèse en utilisant du modafinil
CN101827828B (zh) * 2007-08-07 2013-02-27 普罗萨里克斯有限公司 作为5-羟色胺能调节剂的1,2,4-三唑衍生物
WO2009111031A2 (fr) 2008-03-04 2009-09-11 Intra-Cellular Therapies, Inc. Procédés de traitement de symptômes vasomoteurs
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
TWI368512B (en) * 2009-04-30 2012-07-21 Univ Kaohsiung Medical Pharmaceutical compositions comprising chlorophenyl piperazine derived compounds and use of the compounds in producing medicaments
WO2012072665A1 (fr) 2010-11-30 2012-06-07 Pharmaneuroboost N.V. Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine
CN104402842A (zh) * 2014-11-19 2015-03-11 苏州乔纳森新材料科技有限公司 一种哌嗪类药物中间体的合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
IT1052119B (it) * 1972-10-16 1981-06-20 Sigma Tau Ind Farmaceuti Derivati del triazolinone e procedimento per la loro preparazione

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399693A (en) * 1984-04-17 1995-03-21 British Technology Group Limited Substituted piperazine-2-carboxylic acids and derivatives thereof
US5595983A (en) * 1984-04-17 1997-01-21 British Technology Group Limited Substituted piperazine 2-carboxylic acids useful in the treatment of central nervous system disorders

Also Published As

Publication number Publication date
ES510449A0 (es) 1983-04-16
DK158728C (da) 1990-12-03
KE3711A (en) 1987-04-30
DE3209557C2 (fr) 1993-07-15
SE8201631L (sv) 1982-09-17
IT1148137B (it) 1986-11-26
GB2096137B (en) 1985-01-03
IT8247978A0 (it) 1982-03-12
CA1198436A (fr) 1985-12-24
FR2501690A1 (fr) 1982-09-17
SG30287G (en) 1987-07-17
GR76076B (fr) 1984-08-03
GB2096137A (en) 1982-10-13
AU8117082A (en) 1982-09-23
DE3209557A1 (de) 1982-12-09
NL190757C (nl) 1994-08-01
FI820856L (fi) 1982-09-17
JPS57159774A (en) 1982-10-01
DK158728B (da) 1990-07-09
US4338317A (en) 1982-07-06
FI73670C (fi) 1987-11-09
BE892503A (fr) 1982-09-15
FI73670B (fi) 1987-07-31
YU52582A (en) 1985-06-30
ES8305756A1 (es) 1983-04-16
IE820589L (en) 1982-09-16
KR880001374B1 (ko) 1988-07-29
NL8201021A (nl) 1982-10-18
HK4788A (en) 1988-01-29
CH649539A5 (de) 1985-05-31
NL970014I1 (nl) 1997-06-02
NL970014I2 (nl) 1997-09-01
YU43256B (en) 1989-06-30
IE52788B1 (en) 1988-03-02
AU555888B2 (en) 1986-10-16
AT384022B (de) 1987-09-25
KR830009089A (ko) 1983-12-17
ZA821359B (en) 1983-01-26
DK112582A (da) 1982-09-17
FR2501690B1 (fr) 1985-07-05
LU84011A1 (fr) 1983-02-22
MX9203176A (es) 1992-07-01
ATA104582A (de) 1987-02-15
NL190757B (nl) 1994-03-01
JPH0237353B2 (fr) 1990-08-23
CY1373A (en) 1987-08-07

Similar Documents

Publication Publication Date Title
SE447256B (sv) 2-fenoxialkyl-1,2,4-triazol-3-oner, deras framstellning och farmaceutisk komposition derav
US4487773A (en) 1,2,4-Triazol-3-one antidepressants
US6348472B1 (en) NPY antagonists: spiroisoquinolinone derivatives
AU669160B2 (en) Imidazole, triazole and tetrazole derivatives
HU190997B (en) Process for preparing benzisothiazolyl-and benzisoxazolyl-piperazine derivatives
HU200597B (en) Process for producing sulfonylurea derivatives with antitumour effect
JPH01249769A (ja) 向精神性ヘテロビシクロアルキルピペラジン誘導体
CZ9797A3 (en) Triazole derivative, process of its preparation and pharmaceutical composition containing thereof
SE465928B (sv) 1,2,4-triazolonfoereningar med antidepressiv aktivitet, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
HU204034B (en) Process for producing new 1,3,4,5-tetrahydrobenz(c,d)indole derivatives and pharmaceutical compositions comprising such compounds
US4564613A (en) Pyridoindole derivatives, compositions and use
EP0077983A1 (fr) Dérivés de triazine, leur procédé de préparation et les compositions pharmaceutiques les contenant
CA1177830A (fr) Hexahydro-trans- et tetrahydropyridoindole utilises comme agents neuroleptiques
US4575555A (en) 4-(3-Chlorophenyl)-1,2,3,6-tetrahydropyridine derivative
US4386091A (en) 2-Phenoxyalkyl-1,2,4-triazol-3-one antidepressants
HUT51615A (en) Process for producing new 3,4,5-substituted 4h-1,2,4-triazoles and pharmaceutical preparations containing them
Watanabe et al. Synthesis of novel succinamide derivatives having the 5, 11-dihydro-6H-pyrido [2, 3-b][1, 4] benzodiazepin-6-one skeleton as potent and selective M2 muscarinic receptor antagonists. I
HUT73969A (en) New imidazolo-quinoxalinone derivatives substituted with heterocycles and pharmaceutical compositions containing them
KR880001375B1 (ko) 항우울증 치료제인 2-펜옥시알킬-1,2,4-트리아졸-3-온 및 그의 제조방법
GB2111988A (en) Benzo-fused heterocyclic compounds

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 8201631-2

Format of ref document f/p: F

SPCF Application for supplementary protection certificate filed

Free format text: 9690014, 951220

SPCG Supplementary protection certificate granted

Free format text: 9690014, 951220, EXPIRES: 20070315

NUG Patent has lapsed

Ref document number: 8201631-2

Format of ref document f/p: F